玛曲| 沈丘| 永定| 定西| 大埔| 长白| 乳源| 高淳| 新竹县| 青龙| 延寿| 合肥| 洛阳| 郫县| 普定| 普洱| 宁夏| 临清| 喀喇沁旗| 蒲县| 黄岩| 镇赉| 平度| 防城区| 张湾镇| 务川| 鄂伦春自治旗| 赣州| 宁德| 田东| 扎鲁特旗| 迁安| 宿迁| 石渠| 沁阳| 平房| 六枝| 鄂尔多斯| 公安| 新巴尔虎左旗| 中卫| 蒲江| 辰溪| 普宁| 增城| 杭锦旗| 自贡| 修文| 元氏| 安达| 道县| 东海| 和龙| 呼和浩特| 连山| 岗巴| 邕宁| 宁化| 大关| 清远| 大同县| 鹰潭| 呼伦贝尔| 云阳| 定日| 喀喇沁左翼| 阜宁| 嘉祥| 金沙| 抚顺县| 明光| 金川| 达拉特旗| 丰润| 永定| 莫力达瓦| 建阳| 安义| 南岔| 荥经| 高雄县| 郑州| 花都| 苗栗| 绥中| 忻城| 新津| 响水| 宜君| 新县| 水城| 陵县| 丰顺| 鹰潭| 澜沧| 株洲县| 淳化| 平昌| 安义| 醴陵| 闻喜| 册亨| 科尔沁右翼中旗| 惠农| 鸡西| 桦甸| 洪洞| 景德镇| 濮阳| 泸定| 改则| 新邵| 麦盖提| 井冈山| 丰润| 台江| 格尔木| 永平| 弓长岭| 通江| 安远| 贵阳| 龙里| 陇南| 金州| 嘉祥| 儋州| 永宁| 头屯河| 围场| 惠水| 昭觉| 南充| 阿合奇| 雅江| 惠安| 日照| 岳池| 崇明| 澜沧| 屏东| 武陟| 忻州| 乡城| 塔河| 郫县| 建水| 长汀| 同安| 鄄城| 梓潼| 平川| 鞍山| 马边| 枞阳| 达拉特旗| 乌伊岭| 东海| 杭锦旗| 庆安| 泰州| 台江| 平阴| 嘉定| 会理| 张掖| 瓯海| 富蕴| 乌当| 简阳| 应城| 合川| 祁阳| 禹城| 芦山| 平阴| 商丘| 绥棱| 威宁| 四平| 番禺| 庐江| 富平| 郧县| 清镇| 扶风| 新津| 乐安| 周口| 胶州| 天祝| 成武| 怀柔| 瓯海| 台前| 小金| 岳普湖| 故城| 滨州| 漳浦| 乌伊岭| 砚山| 色达| 黄山区| 东丰| 孙吴| 广饶| 汤阴| 电白| 灵璧| 遂川| 襄汾| 拜泉| 富源| 澧县| 民乐| 南木林| 寿县| 木里| 江孜| 大田| 伊春| 石嘴山| 罗定| 安县| 宁津| 阿拉尔| 曲沃| 察哈尔右翼中旗| 北宁| 耿马| 乐昌| 宁化| 清远| 潼关| 新疆| 淅川| 歙县| 马鞍山| 全州| 雷州| 阿城| 乳源| 福山| 太和| 化德| 荣县| 宝丰| 黄平| 平川| 思南| 新巴尔虎右旗| 临洮| 林芝镇| 蓬溪| 陵水| 吉林| 奉新| 阿勒泰| 札达| 乾安| 潮安| 六安| 腾冲| 百度

中华预防医学会编辑专业委员会第四届委员会换届

2019-07-17 14:57 来源:中国日报网河南

   中华预防医学会编辑专业委员会第四届委员会换届

  百度做了四届人大代表的谭旭光无疑是后者,是非功过如何评,他都是一个印记难消的标志性人物。【网民留言仅代表作者个人意见,不代表人民网观点】留言方式:

规范评估依据。要鼓励勤劳脱贫,拒绝懒惰,让需要脱贫的人通过自己的辛勤劳动达到脱贫的目标。

  天津网友讲道,“地铁站、公交站,都是‘黑车’,很多都是违规拼车,非常不安全,还有的时候坐不下人硬往里塞。说不尽的一汽,道不完的红旗,接下来让我们看看,红旗品牌将如何崛起。

  《地方领导留言板》将群众分散的意见汇集起来,建立起固定机制回应人民网网民留言,有助于提高人民群众的满意度。太可笑了,专业的上市公司宝景宝马4s店近一年的时间把我的新车拆了个稀巴烂,竟然没有确定哪个地方异响,还要求车主自己掏腰包进货购买修理工怀疑的众多部位,而且还不能保证解决异响问题。

业界对吉利的认知态度,基本是从轻视-正视-重视的轨迹演变的。

  抓政策措施。

    这次两会上,谭旭光向习总书记汇报了四个方面的内容。  值得一提的是,福田欧马可S3超级轻卡和飞碟缔途两款车型因在操控性和可靠性方面表现卓越,被分别授予“冰雪操控王”和“极限可靠卡车”奖项。

  对“黑车”的治理有关部门确实做了不少工作,但成效并不明显。

  推动科技创新和经济社会发展深度融合。钻石王老五寻亲记在3月25日召开的2018年中国(深圳)IT领袖峰会上,李小加作了一个比喻,独角兽前身是王老五,公司寻求资方的过程被称为王老五寻亲记,后来王老五就变成了钻石王老五,投资者是新娘,交易所监管层是岳父,政府、公众、专家以及媒体就是岳母。

    “在中国卡车市场消费更新迭代的过程中,权威的产品测试将有利于推动产品技术的进步,我们希望通过卡车极限挑战赛的形式,打造国内卡车行业最具专业度、且最具影响力的测评品牌,为行业发展贡献一份力量。

  百度今年我们欣逢改革开放40周年,那一年,他高中毕业进入潍柴开启人生职业,40年没换过单位,没离开过本行,可谓心无旁骛40年。

    《暂行规定》还明确,广西各市党委、政府和区直有关部门要明确一名领导负责协调此项工作,坚持上级交办和主动认领相结合,制定具体可行的实施办法,切实做到守土有责,守土负责,守土尽责。在3月22日上午,5辆百度的自动驾驶车辆已经跑上了荣华中路,在公里的道路上进行路测。

  百度 百度 百度

   中华预防医学会编辑专业委员会第四届委员会换届

 
责编:

中华预防医学会编辑专业委员会第四届委员会换届

Source: Xinhua| 2019-07-17 17:20:33|Editor: Yamei
Video PlayerClose
百度 管道入户费和水费成为阻碍自来水入户的“拦路虎”。

Xinhua Headlines: Chinese Nobel laureate's team resolves artemisinin resistance in malaria treatment

Chinese Nobel laureate Tu Youyou receives an interview with Xinhua at home in Beijing, capital of China, June 12, 2019. (Xinhua/Zhou Ning)

BEIJING, June 17 (Xinhua) -- Chinese Nobel laureate Tu Youyou announced Monday that her team has proposed solutions to the problem of artemisinin resistance, providing new evidence that artemisinin is still "the best weapon" against malaria, the world's No. 1 insect-borne infectious disease.

As the winner of the 2015 Nobel Prize for the discovery of artemisinin, Tu said that the drug resistance has remained a big challenge to fighting malaria.

Tu's team has been devoted to the study of the resistant mechanism since 2015 and discovered that partial artemisinin resistance is actually a delay in the clearance of malaria parasites from the bloodstream following treatment with combination therapy.

The 89-year-old scientist explained that plasmodia can enter a state of dormancy during the three-day Artemisinin Combination Treatment (ACT), while they also develop a resistance to partner drugs. But if the treatment period is extended to five to seven days and the partner drugs are replaced, the artemisinin resistance can be solved and plasmodia can be killed.

A paper on the study was published on the April issue of the New England Journal of Medicine (NEJM).

Pedro L. Alonso, director of the Global Malaria Programme of the World Health Organization (WHO), said the article published by Tu and her colleagues on NEJM, a top peer-reviewed journal, has demonstrated the excellence of her research ability. Billions of malaria cases have been treated through artemisinin-based combination therapies.

Artemisinin and its derivatives are known for their ability to swiftly reduce the number of parasites in the blood of patients with malaria and have saved millions of lives worldwide. WHO recommends ACTs as the first and second line treatment for malaria, which inflicts over 400,000 deaths every year worldwide.

The artemisinin resistance was formerly verified in the Greater Mekong river basins.

Tu said that treatment failures with ACTs are often directly attributed to the partner drug, which can be addressed by replacing the partner drug. For example, mefloquine plus artesunate can be switched to DHA with piperaquine if the former fails to deliver positive results.

Artemisinin substances are extracted from Qinghao, a kind of Chinese medicinal herb which has been used for more than 2,000 years in China for treating infectious diseases.

Since 2017, no malaria cases have been reported in China, indicating that the epidemic has been eradicated in the country. China has continued to carry out research on malaria control and prevention and develop artemisinin-based antimalarial drugs for the fight against the disease globally.

"Global malaria control is in line with the thrust of the Chinese government's initiative to build a community with a shared future for humanity," said Alonso. "The antimalarial research work carried out by Tu Youyou's team is groundbreaking, outstanding and immeasurable."

During the past three years of research, Tu's team has found that Artemisinins are also highly effective in treating Lupus Erythematous. Collaborating with 15 institutes nationwide, her team started clinical trials of the treatment in May 2018.

So far, 14 out of 500 applied domestic and foreign volunteer patients have been treated with the therapy. No unanticipated negative effects occurred. The three-phase trials will continue with an appraisal for China's official approval of the therapy to be expected around 2026.

Tu's Artemisinins-based research has helped draw more international attention to Traditional Chinese Medicine (TCM). Oxford University has invited Tu to add a chapter to the Oxford Medical Textbook (6th Edition).

The 6,000-word chapter entitled "Traditional Medicine Exemplified by Traditional Chinese Medicine" has been finalized. It is divided into four parts, explaining TCM, Artemisinin and other TCM's discovery history, their mechanisms and clinical applications. In April, Oxford University Press, the publisher, began proofreading the book.

Professor Timothy M. Cox, the editor of the Oxford Textbook of Medicine, said Tu Youyou's team has accomplished the work of integrating traditional Chinese and Western medicine. The chapter on TCM is important and in-depth so the world medical community can have a deep understanding of TCM.

Currently, the main challenge of TCM lies in the differences of evidence-based medicine, prohibiting TCM drugs including Artemisinins to enter the world's mainstream pharmaceutical markets. "All scientific research must be supported by solid data, evidence and well-designed protocols in order to comply with international medical standards and be accepted by the international community," said Alonso.

Although Chinese antimalarial drugs are highly effective and popular in African countries, the WHO spends a significant amount of its annual government procurement antimalarial funding mainly on foreign rather than Chinese pharmaceutical companies.

Xie Zheng, a technical officer of the WHO, said the production lines of Chinese pharmaceutical enterprises do not meet the WHO GMP technical standards and are difficult to obtain pre-qualification. They can only commission foreign pharmaceutical enterprises that meet the standards or go abroad in the way of government procurement.

China has made it a national strategy to encourage evidence-based medicine research and GMP standard construction so pharmaceutical enterprises can speed up the transformation of their production lines to obtain WHO certification and approval, said Liao Fulong, a senior researcher with Tu's team.

(Video reporters: Wang Junlu, Zhou Ning, Luo Guojun, Gai Boming; Video editor: Liu Xiaorui)

   1 2 Next  

KEY WORDS:
EXPLORE XINHUANET
010020070750000000000000011103261381506051
百度